- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CytoSorbents Receives $325,000 in Non-Dilutive Funding
CytoSorbents Corporation (NASDAQ:CTSO) announced the receipt of $324,606, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA).
CytoSorbents Corporation (NASDAQ:CTSO) announced the receipt of $324,606, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA).
According to the press release:
Funds will be used to help expand manufacturing of CytoSorb® and support sales of CytoSorb® internationally.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated:
CytoSorbents has grown internationally to more than 60 employees and consultants, fueled by increasing usage and adoption of our flagship product, CytoSorb®. We are proud to be driving job growth as a U.S. vertically-integrated medical device manufacturer of CytoSorb® right here in New Jersey, enabling tight control over quality and attractive gross margins of more than 60% which are expected to increase with volume manufacturing. Over the past 7 years, we have been awarded more than $9.0 million in non-dilutive government grants, contracts and other funding, an important part of our overall financing strategy. We thank the NJEDA for their continued support.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â